Workflow
康弘药业:注射用KH815获药物临床试验批准
KHPGKHPG(SZ:002773) news flash·2025-04-16 11:34

Core Viewpoint - Kanghong Pharmaceutical's subsidiary, Kanghong Biotech, has received approval from the National Medical Products Administration for the clinical trial application of its injectable KH815, a novel antibody-drug conjugate targeting TROP2 for advanced solid tumors [1] Group 1 - Kanghong Biotech's KH815 is a self-developed drug with potential anti-resistance properties [1] - The drug is specifically designed for the treatment of advanced solid tumors [1]